Dopamine D2 occupancy as a biomarker for antipsychotics: Quantifying the relationship with efficacy and extrapyramidal symptoms

AAPS Journal

Volumn 13, Issue 1, 2011, Pages 121-130

  De Greef, Rik ^a   Maloney, Alan ^b,c   Olsson Gisleskog, Per ^b,c   Schoemaker, Joep ^a   Panagides, John ^d  

^a NV ORGANON   (Netherlands)

^b CERTARA   (United States)

^c Exprimo Consulting   (Belgium)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Asenapine; Dopamine D2 receptors; Mathematical models

Indexed keywords

ASENAPINE; BIOLOGICAL MARKER; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE; ZIPRASIDONE; FUSED HETEROCYCLIC RINGS;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITIVE AND NEGATIVE SYNDROME SCALE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; SIMPSON ANGUS SCALE; TREATMENT OUTCOME; ALGORITHM; BIOASSAY; BIOAVAILABILITY; CHEMICALLY INDUCED DISORDER; COMPUTER SIMULATION; DOSE RESPONSE; DRUG EFFECT; EXTRAPYRAMIDAL SYNDROME; METABOLISM; PATHOPHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL MODEL;

ALGORITHMS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BIOLOGICAL AVAILABILITY; BIOLOGICAL MARKERS; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDPOINT DETERMINATION; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MODELS, STATISTICAL; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 79951996416     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-010-9247-4     Document Type: Article

References (53)

1. Lieberman JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry. 2007;68:e04.
2. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999;156:286-93.
3. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992;49:538-44.
4. Pani L, Pira L, Marchese G. Antipsychotic efficacy: relationship to optimal D(2)-receptor occupancy. Eur Psychiatry. 2007;22:267-75.
5. 2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry. 1996;153: 948-50.
6. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry. 1993;33:227-35.
7. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20:389-409.
8. Saphris® (asenapine sublingual tablets). Full prescribing information, Schering Corporation, a subsidiary of Merck & Co., Inc, Whitehouse Station, NJ; 2010.
9. European Medicines Agency. Sycrest asenapine. 2010. http://www.ema. europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001177/ human-med-001379.jsp&murl=menus/medicines/medicines.jsp&mid= WC0b01ac058001d124&jsenabled=true. Accessed 28 September 2010.
10. Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009;23:65-73.
11. 2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men. Psychopharmacology Berl. 1997;131:339-45.
12. Data on file. Summit, NJ: Merck; 2010.
13. Geodon® (ziprasidone). Full prescribing information, Pfizer Inc., New York, NY; 2009.
14. Cheng YF, Paalzow LK, Bondesson U, Ekblom B, Eriksson K, Eriksson SO, et al. Pharmacokinetics of haloperidol in psychotic patients. Psychopharmacology Berl. 1987;91:410-4.
15. Heyden S. Risperidone expert report (Serial No. R64 766). April 1992.
16. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-76.
17. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-9.
18. Risperdal® (risperidone). Full prescribing information. Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., Titusville, NJ; 2009.
19. Zyprexa. Eli Lilly and Company, Indianapolis, IN; 2010.
20. Friberg LE, de Greef R, Kerbusch T, Karlsson MO. Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia. Clin Pharmacol Ther. 2009;86:84-91.
21. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157:514-20.
22. Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2010;30:106-15.
23. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1159-72.
24. 2C receptor polymorphisms separately associate with positive and negative symptom response. Eur Neuropsychopharmacol. 2005;15:143-51.
25. Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE, et al. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry. 1998;44:1099-117.
26. Lane HY, Lee CC, Liu YC, Chang WH. Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics. Pharmacogenomics. 2005;6:139-49.
27. 2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol. 1995;15:19S-23S.
28. 2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology Berl. 1998;135:119-26.
29. Gefvert O, Lundberg T, Wieselgren IM, Bergstrom M, Langstrom B, Wiesel F, et al. D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol. 2001;11:105-10.
30. 2 receptors, yet occupy high levels of these receptors. Mol Psychiatry. 1998;3:123-34.
31. 2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci. 2000;25:161-6.
32. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry. 2007;68:1492-500.
33. 2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology Berl. 1992;106:433-8.
34. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology. 1997;16:1-7.
35. 2 occupancy: a positron emission tomographic study. J Clin Psychopharmacol. 1998;18:82-3.
36. 2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology Berl. 1993;110:265-72.
37. 2A receptor occupancy in schizophrenic patients. Am J Psychiatry. 1999;156:869-75.
38. 11C-raclopride. Psychopharmacology Berl. 1993;112:308-14.
39. 2 receptors by the neuroleptic ziprasidone (CP-88, 059-01) determined by positron emission tomography. Psychopharmacology Berl. 1996;124:141-7.
40. Beasley Jr CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14:111-23.
41. Beasley Jr CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology Berl. 1996;124:159-67.
42. Beasley Jr CM, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol. 1997;7:125-37.
43. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151:825-35.
44. Borison R, et al. Risperidone versus haloperidol versus placebo in the treatment of schizophrenia. Clinical Research Report No. RIS-USA-9001, N83170. Piscataway, NJ: Janssen; 1991.
45. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry. 1995;166:712-26.
46. Clinical Report: RIS-USA-72. 1997. NDA 20588/S002.
47. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology. 1999;20:491-505.
48. Keck Jr P, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology Berl. 1998;140:173-84.
49. Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 1998;18:296-304.
50. Clinical Report: Study 104. 1998. NDA 20825.
51. Clinical Report: Study 115. 1998. NDA 20825.
52. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry. 1997;42:233-46.
53. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry. 1997;154:782-91.